

**Claim Nos. HP-2017-000079 and HP-2018-000009**

**IN THE HIGH COURT OF JUSTICE  
BUSINESS AND PROPERTY COURTS OF ENGLAND AND WALES  
INTELLECTUAL PROPERTY LIST (CHD)  
PATENTS COURT**

**B E T W E E N:**

Aspire Action:

**ALLERGAN, INC.  
ALLERGAN LIMITED**

Claimants in HP-2017-000079

**and**

**ASPIRE PHARMA LIMITED**

Defendant in HP-2017-000079

Accord Action:

**ACCORD HEALTHCARE LIMITED**

Claimant in HP-2018-000009

**and**

**ALLERGAN, INC.**

Defendant in HP-2018-000009

---

**ANNEX 1**

---

**Claims:**

1. A composition comprising from 0.005% to 0.02% bimatoprost by weight and from 100 ppm to 250 ppm benzalkonium chloride, wherein said composition is an aqueous liquid which is formulated for ophthalmic administration.
2. The composition of claim 1 which further comprises an effective amount of EDTA.
3. The composition of claim 2 wherein the concentration of benzalkonium chloride is from 150 ppm to 200 ppm.
4. The composition of claim 3 having a pH of 7.4 which consists essentially of 0.015% bimatoprost, 200 ppm benzalkonium chloride, from 0 to 0.03% EDTA, a phosphate buffer, NaCl, and water.

5. The composition of claim 1 wherein the concentration of bimatoprost is from 0.01 % to 0.02%.
6. The composition of claim 5 wherein the concentration of bimatoprost is from 0.015% to 0.02%.
7. The composition of claim 6 wherein the concentration of benzalkonium chloride is from 150 ppm to 200 ppm.
8. The composition of claim 7 wherein the concentration of benzalkonium chloride is 200 ppm.
9. The composition of claim 6 which further comprises an effective amount of EDTA.
10. The composition of claim 9 having a pH of 7.4 which comprises 0.015% bimatoprost, 200 ppm benzalkonium chloride, from 0 to 0.03% EDTA, a phosphate buffer, and NaCl.
11. The composition of claim 10 having a pH of 7.4 which consists of 0.015% bimatoprost, 200 ppm benzalkonium chloride, from 0 to 0.03% EDTA, a phosphate buffer, NaCl, and water.
12. The composition of any preceding claim for treating glaucoma or intraocular hypertension in a mammal.
13. The composition of claim 2 comprising from 0.001% to 0.15% EDTA.
14. The composition of claim 13 comprising from 0.01% to 0.1% EDTA.
15. The composition of claim 14 comprising from 0.01% to 0.05% EDTA.
16. The composition of claim 2 comprising from 150 to 250 ppm BAK
17. The composition of claim 5 comprising 0.0125% bimatoprost, 0.02% benzalkonium chloride, 0.268% sodium phosphate dibasic heptahydrate, 0.014% citric acid monohydrate, 0.81% sodium chloride, sufficient sodium hydride and/or hydrochloric acid to adjust the pH to 7.3, and water.
18. [A composition comprising 0.01% bimatoprost, 0.02% benzalkonium chloride, 0.268% sodium phosphate dibasic heptahydrate, 0.014% citric acid monohydrate, 0.81% sodium chloride, and water, wherein the pH is 7.3.](#)